comparemela.com

Latest Breaking News On - Cardiovascular conditions - Page 2 : comparemela.com

Helius Medical Shares Rise 21% After FDA Meeting

By Chris Wack Helius Medical Technologies shares were up 21% to $8.55 after the company said it has concluded its interaction with the U.S. Food and Drug.

Chris wackDrug administrationCenters for medicare medicaid servicesMedical technologiesTransitional coverageEmerging technologiesArticle normalMedical equipment suppliesHealthcare life sciencesRegulation government policyFinancial performanceShare price movement disruptionsCorporate industrial newsCardiovascular conditionsPolitical general newsMedical conditions

At 85, I thought I was having a heart attack, then got this surprising diagnosis

I was huffing and puffing walking the dog. I was mystified. For my advanced age of 85, I have been in good health, then my doctor said I have asthma.

United statesCenters for diseaseIllinois state bather codeDisease controlArticle normalHealth careCardiovascular conditionsPolitical general newsRespiratory tract diseasesLiving lifestyleMedical conditionsGeneral news

Liquidia Shares Down in Premarket as FDA Continues Review of Yutrepia Application

By Adriano Marchese Shares of Liquidia were down in premarket trading on Thursday after it said that the U.S. Food and Drug Administration is still working.

Adriano marcheseRoger jeffsDrug administrationExecutive roger jeffsArticle normalCardiovascular drugsHealthcare life sciencesSpecialized drugs medicationsCardiovascular conditionsPolitical general newsHypertension high blood pressureMedical conditionsGeneral newsHigh blood pressureLife sciencesSpecialized drugs

BridgeBio Gets Up to $1 25 Billion in New Financing

By Colin Kellaher BridgeBio Pharma has secured up to $1.25 billion in new financing, as the biopharmaceutical company gears up for the launch of its.

Bridgebio pharmaColin kellaherDrug administrationBio pharmaBlue owl capitalCanada pension plan investment boardPalo altoBlue owlArticle normalFinancial investment servicesInvestment bankingHealthcare life sciencesBanking creditFinancial servicesInvesting securitiesCorporate funding

Abbott s Volt PFA System Used in Procedures for Patients with Abnormal Heart Rhytms

By Denny Jacob Abbott Laboratories disclosed that the first global procedures have been conducted using its new Volt Pulsed Field Ablation system to treat.

Denny jacobAbbott laboratoriesVolt pulsed field ablationArticle normalHealthcare life sciencesCardiovascular conditionsPolitical general newsMedical conditionsGeneral newsLife sciences

vimarsana © 2020. All Rights Reserved.